BioNTech's Seoul Deadline: Will WCLC Data Confirm Pumitamig's Consistency?

BioNTech's stock price has surged by 21% in US trading following positive Phase-3 data from Moderna and Merck on a melanoma vaccine. This rally is partly due to borrowed enthusiasm from competitors rather than fresh results from BioNTech's own pipeline.

The company faces a moment of reckoning at the World Conference on Lung Cancer (WCLC) in Seoul, where it will present first global data on a novel combination of pumitamig and elfetabart drozuntecan, as well as updated overall survival figures for gotistobart from the Phase-3 PRESERVE-003 study.

Investors are eagerly awaiting the WCLC data to confirm pumitamig's consistency across varying PD-L1 expression levels. A positive outcome would extend the trend of encouraging efficacy seen in previous datasets, including the combination of pumitamig with chemotherapy in first-line non-small cell lung cancer.

Canaccord has raised its price target to $142 and reiterates a buy rating, citing three key clinical data points due by year-end and the upcoming leadership transition as catalysts. However, the stock's current strength represents an advance payment on an event whose outcome is still uncertain.